AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...

Several authors disclosed ties to biopharmaceutical companies. AstraZeneca provided exenatide for the study. Abstract/Full Text ...

A rigorous study that randomly assigned Parkinson’s patients to take exenatide, a relative of ... a type 2 diabetes treatment made by AstraZeneca and sold under the brand name Byetta, or with ...